# US 2012/0255040 A1 · Cell Model and Methods Using the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0255040 A1
- Document ID: US20120255040A1
- Status: Published application
- Kind: A1
- Application number: 13/075,846
- Filed: 2011-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-03-30
- Inventors: Kai Dittmann; Juergen Wienands
- Web page: https://patentgrep.com/patent/US20120255040A1

## CPC

- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A01K 2217/052: inducing gain of function
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates in a first aspect to a cell model containing chondrocytes whereby said chondrocytes contain a first heterologous nucleic acid sequence operably linked with a mb1 promoter sequence. In another aspect, the present invention relates to a cell model, in particular, to a transgenic animal model whose genome comprises a first heterologous nucleic acid sequence encoding a recombinase and/or restriction enzyme operably linked to a chondrocyte specific promoter, and a second heterologous nucleic acid sequence encoding a target peptide of interest wherein the second nucleic acid sequence further comprises recombination sequences or restriction site for the enzyme encoded by the first heterologous nucleic acid sequence. In addition, methods for screening foreign agent or methods for testing the efficacy and/or efficiency of an agent are provided. Said agents are tested for their ability to reduce or prevent or to allow treatment of diseases, disorders or conditions involving arthropathy and/or chondropathy, in particular, spinal malfunction.

## Claims

### Claim 1

A cell model containing chondrocytes whereby said chondrocytes contain a first heterologous nucleic acid sequence operably linked with a mb1 promoter.

### Claim 2 (depends on 1)

The cell model according to claim 1 wherein the first heterologous nucleic acid sequence is transcribed to a coding or non-coding RNA, in particular, a mRNA, tRNA, miRNA, siRNA.

### Claim 3 (depends on 1)

The cell model according to claim 1 wherein the heterologous nucleic acid sequence encodes a polypeptide, in particular, an enzyme.

### Claim 4 (depends on 3)

The cell model according to claim 3 wherein said enzyme is a recombinase, in particular, the Cre recombinase or the FLP recombinase, or said enzyme is a restriction enzyme.

### Claim 5 (depends on 1)

The cell model according to claim 1 wherein the chondrocytes contain a second heterologous nucleic acid sequence encoding a target of interest, like a peptide of interest (POI) whereby said second heterologous nucleic acid sequence which is different from the first heterologous nucleic acid sequence further comprises at least one sequence allowing site-specific recombination of the sequence encoding the POI, in particular, comprising at least one loxP site or FLP recognition target.

### Claim 6 (depends on 5)

The cell model according to claim 5 wherein the POI encoded in the second heterologous nucleic acid sequence is at least one of Ptch1, VDR, PTEN, SOX9, SMO, GLI1, GLI2, GLI3, BMP2, BMP7, RUNX2, PTH, PTHRP, FGF2, GDF5, EXT1, WNT5A, TNFRSF11A, TNFFSF11, in particular, at least one of Ptch1, VDR, PTEN, SOX9, SMO, GLI1, GLI2, GLI3, BMP2, BMP7, or RUNX, like Ptch1.

### Claim 7 (depends on 1)

The cell model according to claim 1 characterised in being a transgenic animal model, in particular, a rodent transgenic animal model, particularly preferred a transgenic mouse model.

### Claim 8

A cell model, in particular, a transgenic animal model, whose genome comprises
a) a first heterologous nucleic acid sequence encoding a recombinase and/or a restriction enzyme operably linked to a chondrocyte specific promoter, and
b) a second heterologous nucleic acid sequence encoding a target of interest, like a peptide of interest (POI) wherein the second nucleic acid sequence further comprises recombination sequences or restriction sites for the enzyme encoded by the first heterologous nucleic acid sequence.

### Claim 9 (depends on 8)

The cell model according to claim 8 wherein the first heterologous nucleic acid sequence contains the mb1 promoter as chondrocytes-specific promoter.

### Claim 10 (depends on 8)

The cell model according to claim 8, wherein the first heterologous nucleic acid sequence encodes a recombinase, in particular, a Cre recombinase or a FLP recombinase.

### Claim 11 (depends on 8)

The cell model according to claim 8 wherein the heterologous nucleic acid sequence is at least one of Ptch1, VDR, PTEN, SOX9, SMO, GLI1, GLI2, GLI3, BMP2, BMP7, RUNX2, PTH, PTHRP, FGF2, GDF5, EXT1, WNT5A, TNFRSF11A, TNFFSF11, in particular, at least one of Ptch1, VDR, PTEN, SOX9, SMO, GLI1, GLI2, GLI3, BMP2, BMP7, or RUNX, preferably, the Ptch1 sequence.

### Claim 12 (depends on 8)

The cell model according to claim 8 wherein the recombination sequence or restriction sites for the enzyme encoded by the first heterologous nucleic acid sequence are recombination sequences selected from one or more loxP sequences or one or more FLP recognition targets.

### Claim 13 (depends on 8)

The cell model according to claim 8 being a transgenic animal model, in particular, a rodent transgenic animal model, like a mouse model.

### Claim 14 (depends on 8)

The cell model according to claim 8 suitable as a model for arthropathy and/or chondropathy, in particular, spinal arthropathy, spinal diseases, disorders or conditions involving hyperproliferation of chondrocytes and malformation of the spine, like rheumatoid arthritis, scoliosis, spondylitis ankylosans and other syndromes of the spine.

### Claim 15 (depends on 14)

The cell model according to claim 14 being a transgenic animal model for spinal ankylosis.

### Claim 16 (depends on 8)

A method of screening for an agent reducing or preventing one or more symptoms of arthropathy and/or chondropathy, in particular, spinal malformation due to hyperproliferation of chondrocytes comprising steps of
(a) providing a cell model according to claim 8;
(b) administering to the cell model an agent to be tested; and
(c) determining whether the agent reduces or prevents one or more symptoms of arthropathy and/or chondropathy, in particular, of spinal malformation due to hyperproliferation of chondrocytes

### Claim 17 (depends on 8)

A method of testing the efficacy and/or efficiency of an agent suspected to allow treatment of diseases, disorders or conditions of arthropathy and/or chondropathy, in particular, involving spinal malformation, like arthropathy of the spine, comprising the step of
(a) providing a cell model according to claim 8;
(b) administering to said cell model an agent suspected to be useful in the treatment of diseases, disorders or conditions of arthropathy and/or chondropathy, in particular, involving spinal malformation, in particular, arthropathy of the spine, and
(c) determining the efficacy and/or efficiency of whether said agent is useful in the treatment of diseases, disorders or conditions of arthropathy and/or chondropathy, in particular, involving spinal malformation, in particular, arthropathy of the spine.
